Bayer investors have been facing a turbulent scenario, with the company's shares witnessing ups and downs. Incidents like inflated earnings due to soccer transfers have raised concerns among the investors, causing a share drop. Despite years of losses, Bayer's stock is charting a significant 40% rebound. The shares dipped 0% at ETR: BAYN, causing analysts to contemplate what comes next. Q2 reports saw a further drop in Bayer's stock.
Bayer has launched Aspirina, Mexico's top pain relief brand, in the US as the Hispanic population reaches 19%. Amid this turmoil, factors have emerged that make Bayer a fresh buy stock. Despite a slump in stock following a firm order to pay more than $2B in the latest Roundup case, Bayer is of the view that the stock might see an upswing starting FY26. Bayer has slashed 12,000 jobs since restructuring.
Shareholder's scrutiny has been attracted by a dip in the price of Bayer share. Amid this scenario, some experts believe that an investment in Bayer stock could pay off, but it isn't for the faint-hearted.
BAYER Stocks News Analytics from Tue, 12 Nov 2024 08:00:00 GMT to Fri, 15 Aug 2025 21:27:31 GMT -
